PriceTargets.com logo

Pyxis Oncology - PYXS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 93.18%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$4.40 As of 04/25/2024 12:28 PM ET
▼ -0.05 (-1.12%)

This chart shows the closing price for PYXS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Pyxis Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PYXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PYXS

Analyst Price Target is $8.50
▲ +93.18% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Pyxis Oncology in the last 3 months. The average price target is $8.50, with a high forecast of $12.00 and a low forecast of $7.00. The average price target represents a 93.18% upside from the last price of $4.40.

This chart shows the closing price for PYXS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 7 polled investment analysts is to buy stock in Pyxis Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/1/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/30/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/29/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/10/2024HC WainwrightReiterated RatingBuy ➝ Buy$7.00Low
3/22/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$7.00Low
3/22/2024HC WainwrightBoost TargetBuy ➝ Buy$4.00 ➝ $7.00Low
2/9/2024BTIG ResearchInitiated CoverageBuy$8.00Low
1/23/2024Leerink PartnrsReiterated RatingOutperformLow
1/23/2024SVB LeerinkInitiated CoverageOutperform$12.00Low
11/30/2023HC WainwrightReiterated RatingBuy$4.00Low
11/8/2023William BlairReiterated RatingOutperformLow
9/5/2023Royal Bank of CanadaInitiated CoverageOutperform$7.00Low
4/26/2023Lifesci CapitalReiterated RatingOutperformLow
3/23/2023Credit Suisse GroupReiterated RatingOutperform$14.00Low
3/22/2023William BlairReiterated RatingOutperformLow
12/1/2022Lifesci CapitalReiterated RatingOutperformLow
11/2/2021Lifesci CapitalReiterated RatingOutperformLow
11/2/2021William BlairReiterated RatingBuyLow
11/2/2021Jefferies Financial GroupInitiated CoverageBuy$25.00Low
11/2/2021Bank of AmericaInitiated CoverageNeutral$16.00Low
11/2/2021Credit Suisse GroupInitiated CoverageOutperform$19.00Low
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.41 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Pyxis Oncology logo
Pyxis Oncology, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody, which is in Phase 1 clinical trial for the treatment of solid tumors, including non-small cell lung cancer (NSCLC) without driver mutations/translocations, breast cancer, endometrial cancer, thyroid cancer, kidney cancer, cholangiocarcinoma, bladder cancer, colorectal cancer, and head and neck squamous cell carcinoma. The company's antibody drug conjugate product candidate is PYX-201, an investigational human immunoglobulin G1 isotype site-specifically conjugated, which is in Phase 1 clinical trial for solid tumors, including NSCLC, hormone receptor-positive breast cancer, ovarian cancer, thyroid cancer, pancreatic ductal adenocarcinoma, soft tissue sarcoma, hepatocellular carcinoma, and kidney cancer. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $4.40
Low: $4.32
High: $4.54

50 Day Range

MA: $5.15
Low: $3.65
High: $6.59

52 Week Range

Now: $4.40
Low: $1.35
High: $6.85

Volume

118,026 shs

Average Volume

784,471 shs

Market Capitalization

$255.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Pyxis Oncology?

The following sell-side analysts have issued reports on Pyxis Oncology in the last year: BTIG Research, HC Wainwright, Leerink Partnrs, Lifesci Capital, Royal Bank of Canada, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for PYXS.

What is the current price target for Pyxis Oncology?

4 Wall Street analysts have set twelve-month price targets for Pyxis Oncology in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 90.6%. SVB Leerink LLC has the highest price target set, predicting PYXS will reach $12.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $7.00 for Pyxis Oncology in the next year.
View the latest price targets for PYXS.

What is the current consensus analyst rating for Pyxis Oncology?

Pyxis Oncology currently has 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PYXS will outperform the market and that investors should add to their positions of Pyxis Oncology.
View the latest ratings for PYXS.

What other companies compete with Pyxis Oncology?

Other companies that are similar to Pyxis Oncology include Nektar Therapeutics, Inozyme Pharma, Xeris Biopharma, Nanobiotix and XBiotech. Learn More about companies similar to Pyxis Oncology.

How do I contact Pyxis Oncology's investor relations team?

The company's listed phone number is 617-221-9059 and its investor relations email address is [email protected]. The official website for Pyxis Oncology is www.pyxisoncology.com. Learn More about contacing Pyxis Oncology investor relations.